{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:42:56Z","timestamp":1788316976947,"version":"build-2803163510"},"reference-count":22,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["KMU-TC113B02"],"award-info":[{"award-number":["KMU-TC113B02"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-12A1-CG-CO-06-2225-1"],"award-info":[{"award-number":["NHRI-12A1-CG-CO-06-2225-1"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-13A1-CG-CO-06-2225-1"],"award-info":[{"award-number":["NHRI-13A1-CG-CO-06-2225-1"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-14A1-CG-CO-06-2225-1"],"award-info":[{"award-number":["NHRI-14A1-CG-CO-06-2225-1"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer's disease (AD) is the leading cause of dementia worldwide, yet long-term persistence with acetylcholinesterase inhibitors remains suboptimal in routine practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare real-world treatment persistence among patients with mild to moderate AD receiving oral donepezil, rivastigmine capsules, or transdermal rivastigmine patches, and to identify factors influencing discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, 1062 patients aged \u226565 years with newly diagnosed AD were identified from a hospital registry between 2015 and 2019 and followed through 2021. Treatment persistence was evaluated by duration and 1-year continuation rates. Discontinuation was defined as a prescription gap exceeding 90 days. Multivariable Cox proportional hazards models were used to identify predictors of discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients receiving donepezil had significantly longer mean treatment duration (3.03 years) and higher 1-year continuation rates (66.2%) than those receiving rivastigmine capsules (1.81 years, 39.9%) or patches (1.43 years, 45.5%). Both rivastigmine formulations were independently associated with greater discontinuation risk (adjusted hazard ratio [aHR] 1.44 and 1.76, respectively; p\u2009&lt;\u20090.001). Participation in a national dementia care program was the strongest protective factor, associated with a 69% lower discontinuation risk (aHR 0.31; p\u2009&lt;\u20090.001). Higher baseline CASI scores, younger age, and milder cognitive impairment predicted greater persistence, whereas adverse events markedly increased discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Donepezil demonstrated superior real-world persistence compared with rivastigmine. Structured dementia care programs substantially enhanced treatment continuity, underscoring the importance of both pharmacologic choice and system-level support in sustaining long-term therapy in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877251415021","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:34:50Z","timestamp":1769600090000},"page":"443-451","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment persistence with acetylcholinesterase inhibitors in Alzheimer's disease: Real-world evidence from a retrospective cohort study"],"prefix":"10.1177","volume":"110","author":[{"given":"Bo-Lin","family":"Ho","sequence":"first","affiliation":[{"name":"Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Neuroscience Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Feng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaw-Bin","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Chun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Neuroscience Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of Neurology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Han","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Neuroscience Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of Neurology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01124-1"},{"key":"e_1_3_3_3_2","article-title":"Donepezil for dementia due to Alzheimer\u2019s disease","volume":"6","author":"Birks JS","year":"2018","unstructured":"Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev 2018; 6: CD001190.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.489"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1788"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/11531270-000000000-00000"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000051228"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.3.427"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx012"},{"key":"e_1_3_3_10_2","article-title":"Alzheimer's disease and its treatment with a novel transdermal patch therapy: Survey of caregiver experiences","volume":"14","author":"Mart\u00ednez-Lage P","year":"2012","unstructured":"Mart\u00ednez-Lage P, Pepp M. Alzheimer's disease and its treatment with a novel transdermal patch therapy: Survey of caregiver experiences. Prim Care Companion CNS Disord 2012; 14: PCC.11m01142.","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_3_3_11_2","first-page":"86","article-title":"From high doses of oral rivastigmine to transdermal rivastigmine patches: User experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease","volume":"29","author":"Re\u00f1\u00e9 R","year":"2014","unstructured":"Re\u00f1\u00e9 R, Ricart J, Hern\u00e1ndez B, et al. From high doses of oral rivastigmine to transdermal rivastigmine patches: User experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease. Neurologia 2014; 29: 86\u201393.","journal-title":"Neurologia"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.12779\/dnd.2015.14.1.31"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000255578"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-017-0438-x"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2011.7.3.137"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.18.2148"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14251"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610208007011"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2021.17.3.376"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X6273"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000255578"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-017-0067-7"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011832"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251415021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251415021","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251415021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:10:07Z","timestamp":1777371007000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251415021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/13872877251415021"],"URL":"https:\/\/doi.org\/10.1177\/13872877251415021","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}